Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03053440 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
A Phase 3 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 3
- Development phase
- 201
- Enrollment target
NCT03053440 is a Phase 3 study that has completed, run by BeiGene. The registered enrollment target is 201 participants.
The verdict
NCT03053440, a Phase 3 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 201 participants
- Enrollment target
Study Summary
This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
Interventions
- DRUG Ibrutinib
- DRUG BGB-3111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2017-01-25 |
| Est. Completion | 2022-06-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03053440
The ClinicalTrials.gov registry entry for NCT03053440 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibrutinib is the first listed.
NCT03053440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03053440 about?
NCT03053440 is a clinical study titled "A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)". This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
What is the current status of trial NCT03053440?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 201 participants. The study started on 2017-01-25. Estimated completion is 2022-06-21.
What interventions are being tested in trial NCT03053440?
The interventions under investigation include: Ibrutinib (DRUG), BGB-3111 (DRUG).
Who is sponsoring clinical trial NCT03053440?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.